Liu Zhouyang

Spécialisation: Pediatric hematologist
15 années d'expérience
Espace de travail: Chine, Pékin, Beijing Jingdu Children’s Hospital
As a specialist at the clinic, Dr. Liu Zhouyang is Chief Physician and Director of the Hematology Inpatient Ward at Beijing Jingdu Children’s Hospital. He has over 15 years of clinical experience managing complex pediatric blood disorders, including chronic active EB virus infection and refractory hemophagocytic lymphohistiocytosis (HLH). His differentiator is protocol leadership: he led the formulation of the Chinese Expert Consensus on Infant HSCT Procedures (2024 Edition), adopted by over 30 pediatric transplant centers, and he established a national long-term follow-up database for infant transplants with n=326. His individualized HSCT approach is described through a “precision conditioning–dynamic immune regulation–multi-dimensional functional protection” framework.
Dr. Liu Zhouyang is a specialist at the clinic and Chief Physician/Director of the Hematology Inpatient Ward at Beijing Jingdu Children’s Hospital. With over 15 years of experience, he manages high-risk pediatric blood disorders including CAEBV and refractory HLH. His differentiator is protocol leadership for infant HSCT: he led the 2024 Chinese Expert Consensus on Infant HSCT Procedures, adopted by over 30 transplant centers, and created a national long-term follow-up database for n=326 infant transplants.

Services du médecin

Où en sommes-nous ?

1 de 3

Les détails sur ce médecin sont exhaustifs et clairs

Fortement en désaccord

Fortement d’accord

Qualifications

Dr. Liu Zhouyang’s work is closely tied to infant HSCT—especially for high-risk pediatric blood disorders where timing and protocol details matter. As a specialist at the clinic, he serves as Chief Physician and Director of the Hematology Inpatient Ward at Beijing Jingdu Children’s Hospital. He has over 15 years of clinical experience managing complex pediatric blood disorders, including chronic active EB virus infection and refractory hemophagocytic lymphohistiocytosis (HLH). Beyond bedside care, he led the formulation of the Chinese Expert Consensus on Infant HSCT Procedures (2024 Edition), which was adopted by over 30 pediatric transplant centers. He also established a national long-term follow-up database for infant transplants with n=326 through the “Multi-Center Research Project on Post-HSCT Functional Recovery.”

Work experience

Chief Physician and Director of the Hematology Inpatient Ward — Beijing Jingdu Children’s Hospital.

Clinical focus and techniques

Dr. Liu’s HSCT strategy is built around individualized protocols for infants under 1 year old and multidisciplinary risk management.

Hematopoietic stem cell transplantation (HSCT) protocols for infants under 1 year old.
“Precision conditioning–dynamic immune regulation–multi-dimensional functional protection” individualized HSCT protocol approach.
Led formulation of the Chinese Expert Consensus on Infant HSCT Procedures (2024 Edition).

Professional societies and certifications

No specific society memberships or certifications are listed in the provided materials.

Academic output

His academic impact is reflected in consensus leadership and national follow-up database establishment for infant HSCT (n=326).

Courses and advanced training

No named courses or teaching activities are specified in the provided materials.

For families considering HSCT, the clinic provides inpatient hematology care and protocol-driven follow-up planning. Dr. Liu Zhouyang’s clinical focus includes CAEBV and refractory HLH, with HSCT as a central therapeutic pathway for high-risk pediatric cases.